Perspectives: Published Editorials and Industry Updates

UCSF Launches Pharmacogenomics Program to Enhance Safety for GI Cancer Patients

October 14, 2025

See how UCSF Health embedded DPYD and UGT1A1 testing into GI oncology care to personalize fluoropyrimidine and irinotecan dosing, reduce severe toxicity risk, and streamline PGx workflow.

Outpatient Administration of BiTEs in Community Oncology Clinics

October 14, 2025

Explore how community oncology clinics are approaching outpatient BiTE therapy, including step-up dosing, CRS and ICANS monitoring, standardized protocols, and safety planning.

Finding Financial Assistance for Cancer Treatment Can Be a Real Challenge for Patients And Their Families

October 14, 2025

Explore PAN Foundation assistance options for oncology patients, including copay grants, what to do when funds are closed, and tools to track funding opportunities.

A Novel Scoring Framework to Analyze & Improve Access Pathways to Oral Oncology Therapies

October 14, 2025

Discover a novel scoring framework that helps oncology teams evaluate access barriers to oral oncology therapies and support faster, more transparent treatment starts.

Prostate Cancer: Imaging and Therapy Options from an Oncology Perspective

October 14, 2025

Explore key updates in prostate cancer imaging and therapy, including PSMA PET access, tracer options, and radiopharmaceutical sequencing in community oncology.

Challenges in IMiD Prescription Management + the Pharmacist’s Role

October 14, 2025

Compare liquid and tissue NGS, learn where each fits best, and see how combined testing can reduce delays and sharpen treatment selection in major solid tumors.

A Review of Liquid, Tissue-Based and Combined Next-Generation Sequencing

October 14, 2025

Compare liquid and tissue NGS, learn where each fits best, and see how combined testing can reduce delays and sharpen treatment selection in major solid tumors.

Education is Key to Helping Oncology Patients Navigating Evolving Medicare Part D Landscape

October 14, 2025

2025 Medicare Part D changes—especially the $2,000 out-of-pocket cap—helped many oncology patients afford therapy, but created new friction as some patients lost manufacturer assistance eligibility and the “smoothing” option proved confusing and underused.

New Drug Prices Promise Relief, But Will Pose A Challenge For Pharma, Patients

October 14, 2025

A quick look at how the Inflation Reduction Act’s Medicare drug reforms are rolling out—what helps patients (like the Part D out-of-pocket cap) and what could shift costs or access as PBMs and manufacturers respond.

Prevent Cancer Foundation: Leading the Charge in Prevention & Early Detection

February 10, 2026

This article explores how the Prevent Cancer Foundation advances cancer prevention and early detection through research, education, outreach, and advocacy, with insights from CEO Jody Hoyos on how providers and industry partners can support screening access and behavior.